Associated Papers
Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers.
Wilding B et al.
Cancer Discovery, 2025
39248702 (PubMed )
Supplement: cd-24-0306_supplementary_data_table_1_suppst1.xlsx › raw_data_drug_sensitivity_assay
Identifying Actionable Variants Using Capture-Based Targeted Sequencing in 563 Patients With Non-Small Cell Lung Carcinoma.
Jiang H et al.
Frontiers in Oncology, 2021
35186718 (PubMed )
Supplement: Table_1.xlsx › Supplementary_Table_2
Mutational landscape and characteristics of ERBB2 in non-small cell lung cancer.
Wei XW et al.
Thoracic Cancer, 2020
Select a paper to view details